CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed study of bevacizumab in first-line metastatic breast cancer is unlikely to substantiate the magnitude of progression-free survival benefit seen in the E2100 trial, Division of Biologic Oncology Products Director Patricia Keegan says.
You may also be interested in...
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Genentech’s proposal to run a new confirmatory trial of Avastin (bevacizumab) while the first-line metastatic breast cancer claim remains on label was undermined by practical considerations raised at the June 28-29 hearing on CDER's proposal to withdraw the indication.
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Genentech’s proposal to run a new confirmatory trial of Avastin (bevacizumab) while the first-line metastatic breast cancer claim remains on label was undermined by practical considerations raised at the June 28-29 hearing on CDER's proposal to withdraw the indication.
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
FDA Commissioner Margaret Hamburg faces a decision on the future of Avastin’s (bevacizumab) first-line metastatic breast cancer claim that may not be so cut and dried as the Oncologic Drugs Advisory Committee’s unanimous vote favoring the indication’s withdrawal suggests.